Print this page    •   Back to Web version of article

2007 Antiretrovirals in Development Pipeline

By Rob Camp

March 23, 2007


NRTIs, NNRTIs and Protease Inhibitors
Phase of Development NRTI NNRTI PI
Preclinical BPH-218, bis-phosphonate NRTI, U Pittsburgh
C-8 substituent,
BI
AG-1859, Pfizer

Dinucleoside polyphosphates, NRTI "potentiators"
U Miami
GS9148 and GS9148 prodrug, Gilead
GRL-02031, Kumamoto U

DOT-TP, Emory U SMP-717,
Advanced Life Sciences
UIC02031, Kumamoto U, Japan

Compound X, nucleotide-competing indolopyridone, Tibotec
SMP-610, Advanced Life Sciences
SPI-256, Sequoia Pharm

KMMP05, RNase H Inhibitor, NCI
S-DABO derivatives (HIV-1 and -2) and pyrimidinediones, Fudan U, China Beta lactams, University of Debrecen, Hungary

D-FDOC, Emory Univ. Oligodeoxi-nucleotides, U Hospital, Zurich
A-681799, Abbott

4-Ed4T, Kagoshima U PBO-15c, pyrrolobenzoxazepinone, U Siena D5, artificial gp41 MAb, Merck

Thiovir, foscarnet analog, Adventrx
Thiazol derivatives, Inst for Virus Research, Japan

Herpesvirus saimiri, transcription and post-transcription antiviral, Temple U
Methyl derivatives, U South Denmark

Triol, diterpine RTI, Cruz Foundation, Brasil
MV026048 and MIV-170, Medivir

Stampidine, Parker Hughes Institute
Phenylthiazoylamines, Yale U


Branched 3 primers, U Illinois HBY 097 and pyridinone derivatives, Rutgers U

dTTP, U Rochester AR806, Ardea BioSc

E2-FdA, Kumamoto U



DOT, dioxolane thymidine, U Georgia


R12-2, thioaptamer, RNaseH domain blocker, U Texas


Didox, Ribonucleotide reductase (RR) inhibitor, Molecules for Health


Quinolones, Rega Institute


TSAO-T derivatives, U Pittsburgh


Thiostavudines, Showa U


ARC, Howard U

Phase I KP-1461, mutagenic deoxyribo-nucleoside, Koronis
70h, GSK PPL-100, Merck

Alovudine (fosalvudine tidoxil, FLT), Heidelberg Pharma

Phase Ib/II Racivir (PSI 5004), Pharmasset
BILR 355/r, BS, Boehringer Ingelheim


Apricitabine (AVX754), Shire UK-435, 061, Pfizer
  Elvucitabine (ACH-126), Achillion


Phase II
Rilpivirine, TMC-278, Tibotec/J&J
Phase III
Etravirine (TMC125), Tibotec/J&&J

Notes:

On hold or stopped.

link to abstract/background material from CROI 2005.

link to abstract/background material from XIIIth Conference on Retroviruses and Opportunistic Infections, Denver, US, 5-8 February, 2006.


Entry Inhibitors, Integrase Inhibitors, Maturation Inhibitors and Other Drugs
Phase of Development EI* Integrase Inhibitors Maturation Inhibitors** Other
Preclinical Benzothiepine & Benzazepine derivatives, 11f, and TAK-652, CCR5 antagonists, Takeda
L-second generation, Merck
enJS56A1, Escape Inhibitor, U Georgia
RWJ67567, p38 inhibitor, U Penn / J&J

Betulinic Acid Derivatives (BAD), DSB/U North Carolina Carbazole derivative, NIID, Japan
siRNA molecule, CombiMatrix
CNI-1493, Rev inhibitor, Heinrich Pette Institute, Germany

Aprepitant, NK-1R antagonist
810871, GSK Betulinic Acid Derivatives (BAD), U North Carolina Trim5α capsid inhibitor, Dana Farber, NIAID

GBV-C, virus that increases chemokines including RANTES (CCR5 blocker), U Iowa Styrylquinoline derivatives, Bioalliance Pharma ACH-CIP, capsid inhibitor, Achillion
CDK inhibitor,
Gilead

15K & 15D, co-receptor docking inhibitors, NCI V-165, Rega Institute, Belgium
RPI-MN, ReceptoPharm KU-55933, ATM kinase inhibitor, KuDOS Pharma

RC-112 & Retrocyclin-1, θ-Defensins, DASTLR
Mycelium integrasone, Fungal polyketide, Merck UK-201,844, Pfizer RSC-1838, GSK/Shionogi

Indolicidin, NIH GS 9224, Gilead Sciences siRNA molecule, Nef inhibitor, CombiMatrix IM, CDK9 inhibitor, Inst of Human Virology

Pyrrolidine CCR5 receptor antagonists, Merck Beta-diketo acids, U Parma/Sassari, Italy PA1050040-02, Panacos Resveretol, Egr1 gene activator, NCI

IC9564, Duke University
PL-2500, P-5-P derivative, Procyon
MDI-P, electrolyzed free radical, Medical Discoveries

Zinc Finger Protein Nucleases, CCR5 inhibitors, Sangamo Biosciences Monophores, Sunesis
Poly (acrylic) acid, Chinese Academy of Science

MDX-010, anti-CTLA-4 antibody, Medarex AVX-I, Avexa
α-v integrins, irsiCaixa Foundation/Merck

UMIST, Genetic Innovation Network Theophylline, caffeine-related methylxanthine, Thomas Jefferson U

CNI-1493, Rev inhibitor, Cytokine Pharmasciences

NB-2 and NB-64, gp41 coiled coil blocker, Shibo & Kumar ITI-367, Oxadiazol pre-integrase inhibitor, GWU

Curcumin (diferuloylmethane), Tat inhibitor, Jawaharlal Nehru Center, India

AMD-887, CCR5 antagonist, Anormed
Triketoacid IIs, BMS
(12) rev inhibitors, NIH

KD-247, CCR5 inhibitor, Kumamoto U

Glycodendrimers, lipid raft carbohydates, Penn State

SP10, Samaritan

siRNA constructs, rev/tat inhibitors, Beckman Institute

gp120-gp41 disulfide bond, Amsterdam MC, Cornell U, U Illinois Chicago

HRG214, caprine IgG, Virionyx, New Zealand

NSC 13778, gp120 blockers, SAIC-NCI

RPI, nicotinic acetylcholine receptor blocker, NutraPharma

sifuvirtide, fusion inhibitor, Fusogen


Oxadiazols, nuclear localization viral matrix blockers, International Therapeutics

gp41 inhibitors, New York Blood Center


LEDGF-integrase competers, Catholic U Leuven, Belgium

gp41 inhibitors, Locus Pharmaceuticals

SCY-635, Cyclophilin Inhibitor, Scynexis

AMD-3451, CCR5/CXCR4 receptor antagonist, Anormed



Monoclonal FAbs, gp41 blocker, NIH



DP-178, fusion inhibitor, Weizmann Institute



TR-999 and TR-1144, Trimeris/Roche



KRH-3955 and KRH-3140, CXCR4 inhibitors, Kureha Corp



Peptidic CCR5 inhibitor, Selexis



Small molecule gp120 inhibitors, BMS



INCB15050, CCR5 inhibitor, Incyte



HGS101, CCR5 mAb, Human Genome Sciences



ZFN, CCR5 disrupter, Sangamo BioSciences



ROAb12, -13, -14, and -18, CCR5 mAbs, Roche



Genistein, USU Bethesda



TD0232, Avexa/TD



Bifunctional (CD4 and CCR5) inhibitors, U Regensburg


Phase I BMS-378806, gp120 blocker, BMS
GSK364735, GSK/Shionogi
BI-201, Tat inhibiting mAb, BioInvent

TAK-652, Takeda



004, mAB, Human Genome Sciences



Suc-HSA, fusion inhibitor, Sanquin



PF232798, CCR5 inhibitor, Pfizer


Phase I/II or Phase IB PRO-140, MAb,
Progenics


Valproic acid, [Depakote™, Abbott], ACTG

INCB9471, CCR5 inhibitor, Incyte

Bevirimat (PA-457), Budding inhibitor, Panacos

HGS004, CCR5 mAb, Human Genome Sciences


Phase II Vicriviroc, CCR5 antagonist, Schering Plough GS-9137, Gilead



TNX-355, Anti-CD4 MAb, Tanox/Biogen


Phase III Maraviroc, CCR5 antagonist, Pfizer
MK-0518, Merck


Notes:

* entry inhibitors, including CCR5 and CXCR4 receptor binding antagonists and CD4 monoclonal antibodies directed at binding, fusion, and entry.

** includes the later replication stages of Assembly, Budding, and Maturation.

On hold or stopped.

link to abstract/background material from CROI 2005.

link to abstract/background material from XIIIth Conference on Retroviruses and Opportunistic Infections, Denver, US, 5-8 February, 2006.




This article was provided by Treatment Action Group. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art1749.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.